Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Alkem Laboratories' CRO facility at Taloja, Maharashtra, underwent an unannounced US FDA inspection on May 8, 2026. The company reported that no Form 483 observations were issued at the inspection's conclusion, indicating compliance.
May 08 2026 18:05:00
US FDA finds violations at Alkem Labs’ Daman facility after 12-day inspection
Alkem Laboratories' Daman manufacturing facility received 7 observations on Form 483 from the US FDA following an 11-day inspection conducted from April 20 to May 1, 2026. The company has committed to addressing these regulatory findings within the required timeframe.
May 02 2026 16:05:00
Alkem Laboratories Ltd - 539523 - US FDA Inspection At Company'S Manufacturing Facility Located At Amaliya, Daman
Alkem Laboratories' manufacturing facility in Amaliya, Daman, was inspected by the US FDA from April 20 to May 1, 2026. The company received Form 483 with seven observations, which it plans to address within the stipulated timeframe.
May 02 2026 13:05:00
Alkem Laboratories Limited
Alkem Laboratories' manufacturing facility at Amaliya, Daman, was inspected by the US FDA from April 20 to May 1, 2026. The company received Form 483 with seven observations, which it plans to address.
May 02 2026 12:05:00
Alkem Laboratories Limited
Alkem Laboratories received an income tax order from the Deputy Commissioner of Income Tax, Central Circle 8(1), Mumbai, disputing a tax amount of ₹333.38 crores for Assessment Year 2023-24. The company asserts no material financial impact due to available MAT credit and plans to appeal the order, believing it has strong grounds to substantiate its position.
Apr 24 2026 16:04:00
Alkem Laboratories Limited
Alkem Laboratories' CEO & KMP, Dr. Vikas Gupta, has resigned. He will serve until June 30, 2026, to facilitate a smooth transition of responsibilities.
Apr 24 2026 15:04:00
Alkem Laboratories shares crater after CEO Vikas Gupta resigns to pursue new opportunities
Vikas Gupta, CEO of Alkem Laboratories, has resigned from his position to pursue new opportunities, leading to a decline of over 4% in the company's share price in early trade. The company has initiated a handover process for succession.
Apr 24 2026 14:04:00
Read More